Article
TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.
Oncotarget - 14 Mar 2017
Fagerholm Rainer, Khan Sofia, Schmidt Marjanka K, García-Closas Montserrat, Heikkilä Päivi, Saarela Jani, Beesley Jonathan, Jamshidi Maral, Aittomäki Kristiina, Liu Jianjun, Ali H Raza, Andrulis Irene L, Beckmann Matthias W, Behrens Sabine, Blows Fiona M, Brenner Hermann, Chang-Claude Jenny, Couch Fergus J, Czene Kamila, Fasching Peter A, Figueroa Jonine, Floris Giuseppe, Glendon Gord, Guo Qi, Hall Per, Hallberg Emily, Hamann Ute, Holleczek Bernd, Hooning Maartje J, Hopper John L, Jager Agnes, Kabisch Maria, Keeman Renske, Kosma Veli-Matti, Lambrechts Diether, Lindblom Annika, Mannermaa Arto, Margolin Sara, Provenzano Elena, Shah Mitul, Southey Melissa C, Dennis Joe, Lush Michael, Michailidou Kyriaki, Wang Qin, Bolla Manjeet K, Dunning Alison M, Easton Douglas F, Pharoah Paul D P, Chenevix-Trench Georgia, Blomqvist Carl, Nevanlinna Heli
Abstract excerpt
TP53 overexpression is indicative of somatic TP53 mutations and associates with aggressive tumors and poor prognosis in breast cancer. We utilized a two-stage SNP association study to detect variants associated with breast cancer survival in a TP53-dependent manner. Initially, a genome-wide study (n = 575 cases) was conducted to discover candidate SNPs for genotyping and validation in the Breast Cancer...
Read the complete abstract on PubMed